New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCJC-1295 vs Adipotide

CJC-1295 vs Adipotide

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
CJC-1295
Fat Loss & Metabolic
Adipotide
Summary
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
Half-Life
~30 minutes (No DAC) / 6–8 days (with DAC)
Estimated 2-4 hours
Admin Route
SubQ
Subcutaneous, Intravenous (research)
Research
Typical Dose
100 mcg
Not established for humans; primate studies used 0.1-1 mg/kg
Frequency
Once daily, before bed
Daily for 4 weeks (research protocol)
Key Benefits
  • Sustained increase in growth hormone levels
  • Enhanced muscle growth and strength
  • Improved fat metabolism and body composition
  • Better recovery and tissue repair
  • Increased bone density
  • Enhanced immune function
  • Improved skin quality and collagen production
  • Synergistic GH release when combined with GHRPs like Ipamorelin
  • Targeted reduction of white adipose tissue
  • Promotes fat vasculature apoptosis without systemic toxicity
  • Demonstrated significant fat loss in primate studies
  • Potential for visceral and subcutaneous fat reduction
  • Novel non-hormonal mechanism distinct from GLP-1 agonists
  • Explored for obesity and metabolic syndrome
Side Effects
  • Water retention / puffiness
  • Carpal tunnel syndrome (with prolonged use)
  • Injection site irritation
  • Hunger increase (minor)
  • +1 more
  • Renal toxicity observed in primate studies (transient, dose-dependent)
  • Dehydration and electrolyte imbalances in research
  • Weight regain upon cessation
  • Limited human data; side effect profile largely from animal studies
Stacks With